High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood

Gustave Roussy, Cancer Campus, Grand Paris71 enrolled

Overview

The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Medulloblastoma Brain Tumors Neuroectodermal Tumors, Primitive

Interventions

Etoposide, carboplatin, melphalan, cisplatin, thiotepaDRUG

Eligibility

Sex: ALLMax age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Medulloblastoma in patients less than 5 years of age * Brain PNET in patients less than 10 years of age * Histologically documented diagnosis * Body weight of \> 8 kg Exclusion Criteria: * Parents' refusal

Locations (1)

Institut Gustave Roussy

Villejuif, France

RECRUITING

Outcomes

Primary Outcomes

Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age

Progression-free survival of children less than 10 years of age with brain PNET

Secondary Outcomes

Progression-free survival of children less than 5 years of age with metastatic medulloblastoma

Toxicity

Long term sequelae

Central Contacts

Chantal Kalifa, MD

CONTACT

33 1 42 11 4166 kalifa@igr.fr

Agnès Laplanche, MD

CONTACT

33 1 42 11 4127 laplanche@igr.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.